Cutaneous adverse drug reaction: Prospective study of 118 cases

##plugins.themes.academic_pro.article.sidebar##

Published Sep 23, 2013
Download
pdf
Vol. 91 No. 9 (2013): Issue Sep 2013

##plugins.themes.academic_pro.article.main##

Hend Chaabane
Abderrahmen Masmoudi
Meriem Amouri
Sonda Ghorbel
Sonia Boudaya
Serriya Hammami
Khaled Zghal
Hamida Turki
Service de Dermatologie CHU. Hédi Chaker Sfax-Tunisie

Abstract

Background: Few prospective studies are available on the incidence and analysis of the characteristics of adverse cutaneous drug reactions.
aim: To describe the adverse cutaneous reactions, their epidemiologic characteristics as well as the different causative drugs through a prospective hospital study.
methods: A 12-month prospective study was managed in our department of dermatology of the teaching hospital Hedi Chaker of Sfax. Requested information included patient characteristics (associated disorders), drug intake (list and chronology of the drug intake during the 3 weeks preceding the adverse reaction) and characteristics of the skin reaction (type, course). The diagnosis was based on a beam of clinical and anamnestic arguments. The drug imputability was evaluated according to the Begaud’s French method.
results: One hundred eighteen cases were collected. A prevalence of 1.08/100 among patients consulting in dermatology department was estimated. The macular and papular exanthema represented the most frequent clinical aspects (42 cases) followed by acute urticaria (23 cases), photosensitivity (19 cases) and fixed drug eruption (15 cases). Principal imputable drugs were antibiotics, mainly penicillins followed by analgesics and non-steroidal anti-inflammatory.
Conclusion: Although it was monocentric, this study revealed a high frequency of drug-induced dermatitis with different clinical presentation. The high incidence of drug-induced dermatitis induced by antibiotics, analgesics and anti-inflammatory is due to their widespread use, often in self-medication.

Keywords:

Adverse drug reactions, maculopapular rash, antibiotics, anticonvulsants.

##plugins.themes.academic_pro.article.details##

References

  1. Roujeau J.C, Bonnetblanc J.M, Schmutz J.L, Crickx B. Iatrogénie. Diagnostic et prevention des toxidermies. Ann Dermatol Venereol 2002; 129 : S163-9.
  2. Gerson D, Sriganeshan V, Alexis J.B. Cutaneous drug eruptions: A 5-year experience. J Am Acad Dermatol 2008; 59: 995-9.
  3. Bigby M. Rates of cutaneous reactions to drugs. Arch Dermatol 2001; 137: 765-70.
  4. Hernández-Salazar A, Rosales SP, Rangel-Frausto S, Criollo E, Archer-Dubon C, Orozco-Topete R. Epidemiology of adverse cutaneous drug reactions. A prospective study in hospitalized patients. Arch Med Res 2006 ; 37:899-902.
  5. Bousquet P.J, Demoly P. Une synthèse sur l'épidemiologie des hypersensibilités médicamenteuses. Revue Fr Allergol Immunol Clin 2005 ; 45 :626-32.
  6. Fiszenson-Albala F, Auzerie V, Mahe E et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003 ; 149 : 1018-22.
  7. Van der Linden PD, Van der Lei J, Vlug AE, Stricker BH. Skin Reactions to Antibacterial Agents in General Practice. J Clin Epidemiol 1998; 51: 703-8.
  8. Bachot N, Roujeau J.C. Imputabilité médicamenteuse en pratique dermatologique quotidienne. Ann Dermatol Venereol 2000 ; 127: 542-5.
  9. Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments. Therapie 1985 ; 40 : 111-8.
  10. Haramburu F, Miremont-Salamé G, Macquin K. Effets indésirables des médicaments : définitions et imputabilité. Rev Rhum 2002 ; 69 : 346-8
  11. Souissi A, Fenniche S, Benmously R, Ben Jannet S, Marrak H, Mokhtar I. Etude des réactions cutanées aux médicaments dans un centre hospitalo-universitaire à Tunis. Tunis Med 2007; 85:1011-5.
  12. Sharma V.K, Sethuraman G, Kumar B. Cutaneous adverse drug reactions: clinical pattern and causative agents-A six year series from Scandigarh, India. J Postgrad Med 2001; 47: 95-9.
  13. Choon SE, Lai NM. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Indian J Dermatol Venereol Leprol 2012 ;78 :734-9.
  14. Allain H, Pibouin M, Bénéton C, Laudren A, Milon D, Chevrant- Breton J. Poursuite sur 18 mois d'une enquête de pharmacovigilance en dermatologie. Bilan méthodique à 30 mois. Therapie 1987 ;42: 311-5.
  15. Capuano A, Motola G, Russo F et al. Adverse drug events in two emergency departments in Naples, Italy: an observational study. Pharmacol Res 2004 ;50:631-6.
  16. Martin RM, Biswas PN, Freemantle SN, Pearce GL, Mann RD. Age and sex distribution of suspected adverse drug reactions to newly marketed drugs in general practice in England: analysis of 48 cohort studies. Br J Clin Pharmacol 1998; 46: 505- 11.
  17. Bonnetblanc J.M. Réactions cutanées aux médicaments chez l'enfant. Ann Dermatol Venereol 1997; 124: 339-45.
  18. Bonnetblanc JM, Vaillant L, Wolkenstein P. Facteurs prédisposants des réactions cutanées aux médicaments. Ann Dermatol Venereol 1995;122:484-6.
  19. Montastruc JL, Lapeyre-Mestre M, Bagheri H, Fooladi A. Gender differences in adverse drug reactions: analysis of spontaneous reports to a Regional Pharmacovigilance Centre in France. Fundam Clin Pharmacol 2002; 16 : 343-6.
  20. Naldi L, Conforti A, Venegoni M et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999; 48: 839-46.
  21. Rademaker M. Do women have more adverse drug reactions? Am J Clin Dermatol 2001; 2: 349-51.
  22. Kharfi M, Masmoudi A, Bodemer C et al. Dermatite atopique : comparaison des prévalences en France et en Tunisie. Ann Dermatol Venereol 2005; 132:478-9.
  23. Sánchez-Borges M, Capriles-Hulett A. Atopy is a risk factor for non-steroidal anti- inflammatory drug sensitivity. Ann Allergy Asthma Immunol 2000; 84: 101-6.
  24. Renn CN, Straff W, Dorfmüller A, Al-Masaoudi T, Merk HF, Sachs B. Amoxicillin- induced exanthema in young adults with infectious mononucleosis: demonstration of drug-specific lymphocyte reactivity. Br J Dermatol 2002; 147:1166-70.
  25. Saito-Katsuragi M, Asada H, Yokoi S, Niizeki H, Miyagawa S. Ampicillin-induced cutaneous eruption associated with Epstein- Barr virus reactivation. J Am Acad Dermatol 2005; 52 (Suppl 1), S127-8.
  26. Beani JC. Les photodermatoses médicamenteuses: comment les diagnostiquer et les explorer? Rev Med Interne 1995; 16 (Suppl 3): 337s-341s.
  27. Allen J.E. Drug-induced photosensitivity. Clin Pharm 1993; 12: 580-7.
  28. Gould J.W, Mercurio M.G, Elmets C.A. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995; 33 : 551-73.
  29. Murphy GM. Diseases associated with photosensitivity. J Photochem Photobiol B 2001; 64: 93-8.
  30. Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev 2001; 53: 357-79.
  31. Ozkaya-Bayazit E. Specific site involvement in fixed drug eruption. J Am Acad Dermatol 2003; 49:1003-7.
  32. Mahboob A, Haroon TS. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol 1998; 37: 833-8.
  33. Bonnetblanc JM. Toxidermie. Ann Dermatol Venereol 2005; 132: 924-5.
  34. Nussinovitch M, Prais D, Ben-Amitai D, Amir J, Volovitz B. Fixed drug eruption in the genital area in 15 boys. Pediatr Dermatol 2002 ;19 :216-9.
  35. Vaillant L, Berbis P, Chevrant-Breton J, Bonnetblanc JM. Prurit. Ann Dermatol Venereol 2002 ;129(Suppl10): S213-8.
  36. Lorette G, Vaillant L. Pruritus. Current concepts in pathogenesis and treatment. Drugs 1990 ; 39 : 218-23.
  37. Aquilina C, Sayag J. Eczémas par réactogènes internes. Ann Dermatol Venereol 1989 ; 116 : 753-65.
  38. Wolf R, Orion E, Marcos B, Matz H. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol 2005; 23 : 171- 81.
  39. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-85.
  40. Kaufman DW, Kelly JP. Acetyl salicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Clin Pharmacol 2001; 51 : 174-6.
  41. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-7.
  42. Sharma V.K, Sethuraman G, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: A retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venerol Leprol 2008; 74: 238-40.
  43. Romaguera C, Grimalt F, Vilaplana J, Azon A. Erythroderma from carbamazepine. Contact Dermatitis 1989; 20:304-5.
  44. Kamaliah MD, Zaimal D, Mokhtar N, Nazmi N. Erythema multiforme, Steven Johnson Syndrome and toxic epidermal necrolysis in North East Malaysia. Int J Dermatol 1998; 37: 520-3.
  45. Bocquet H, Bagot M, Roujeau J.C. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 1996; 15: 250-7.
  46. Gaig P, García-Ortega P, Baltasar M, Bartra J. Drug Neosensitization During Anticonvulsant Hypersensitivity Syndrome. J Investig Allergol Clin Immunol 2006; 16: 321-6.
  47. Begon E., Roujeau J.C. Syndrome d'hypersensibilité médicamenteuse ou DRESS. Ann Dermatol Venereol 2004; 131: 293-7.
  48. Gupta A, Eggo MC, Uetrecht JP et al. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992; 51: 56-67.
  49. Hanjani NM, Rencic A, Whitmore SE. Pityriasis rosea-like eruption due to bismuth. Cutis 2006; 77: 166-8.
  50. Atzori L, Pinna AL, Ferreli C, Aste N. Pityriasis rosea-like adverse reaction: review of the literature and experience of an Italian drug-surveillance center. Dermatol Online J 2006 ; 12: 1.